CAMBREX CORPORATION (NYSE:CBM) Files An 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

0
CAMBREX CORPORATION (NYSE:CBM) Files An 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

CAMBREX CORPORATION (NYSE:CBM) Files An 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.03.Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

On February 1, 2019, the Board of Directors of Cambrex Corporation approved and adopted an amendment to the Amended and Restated By-Laws of the Company (the “By-Law Amendment”).The purpose of the By-law Amendment was to remove the forum selection provision, and the By-Law Amendment became effective immediately upon its approval by the Board.

The foregoing description of the Amended and Restated By-Laws is qualified in its entirety by reference to the Amended and Restated Bylaws filed as Exhibit 3.1 hereto.

Item 9.01 – Exhibits

(d)Exhibit Index

Exhibit 3.1Amended and Restated By-Laws of Cambrex Corporation

CAMBREX CORP Exhibit
EX-3.1 2 cbm-ex31_6.htm EX-3.1 cbm-ex31_6.htm DRAFT Exhibit 3.1 AMENDED & RESTATED BY-LAWS OF CAMBREX CORPORATION   ARTICLE I – OFFICES   The registered office of Cambrex Corporation (the “Corporation”) in the State of Delaware shall be in the City of Wilmington,…
To view the full exhibit click here

About CAMBREX CORPORATION (NYSE:CBM)

Cambrex Corporation (Cambrex) is a life sciences company. The Company provides products and services for the development and commercialization of new and generic therapeutics. The Company supplies its products and services across the world to generic pharmaceutical companies. Cambrex operates through three segments, which are manufacturing facilities. The Company’s manufacturing facilities are located in the Europe and the United States. The Company’s business consists of the custom development and manufacture of pharmaceutical ingredients derived from organic chemistry. The Company’s products include active pharmaceutical ingredients (APIs), pharmaceutical intermediates and other fine chemicals. The Company’s products and services are sold around the world under trademarks that are owned by the Company. This includes Profarmaco, which is registered around the world as a word and design mark. Its products are sold through a combination of direct sales and independent agents.